Skip to site content

FDA Requests Withdrawal of Lorcaserin

February 13, 2020

The FDA requests the withdrawal of the weight-loss drug lorcaserin from the market due to potential increased risk of cancer.

The FDA has determined that the risk of cancer outweighs the benefits of lorcaserin therapy. A recent clinical trial found an increase in the risk of certain types of cancer, (pancreatic, colorectal, and lung), associated with lorcaserin use.

If you know of a patient who has developed cancer after taking lorcaserin, report it to the MedWatch program as recommended in the Indian Health Manual and include “IHS” in the reporter section (section G).

Instructions for reporting can be found online at the NPTC Pharmacovigilance website.